2-amino-4-(naphth-1-yl)imidazole | 76507-18-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-amino-4-(naphth-1-yl)imidazole
• 英文别名: 4-(naphthalen-1-yl)-1H-imidazol-2-ylamine；5-(Naphthalen-1-yl)-1H-imidazol-2-amine；5-naphthalen-1-yl-1H-imidazol-2-amine
• CAS: 76507-18-1
• 化学式: C₁₃H₁₁N₃
• 分子量: 209.25
• InChiKey: YVHHQTSYHNTIBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-amino-4-(naphth-1-yl)imidazole 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 氯仿 为溶剂， 生成 5-Bromo-4-naphthalen-1-yl-1H-imidazol-2-ylamine
  参考文献：
  名称：

  Nath, J. P.; Mahapatra, G. N., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1980, vol. 19, # 6, p. 526 - 528

  摘要：

  DOI：
• 作为产物：
  描述：

  1-萘乙酮 生成 2-amino-4-(naphth-1-yl)imidazole
  参考文献：
  名称：

  NATH, J. P.;MAHAPATRA, G. N., INDIAN J. CHEM., 1980, 19, N 6, 526-528

  摘要：

  DOI：

文献信息

• [EN] 5-HT2B RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR 5-HT2B
  申请人：PHARMAGENE LAB LTD

  公开号：WO2005012263A1

  公开（公告）日：2005-02-10

  Compounds of formulae: (I), (II), (IIIa), (IIIb), (IVa) and (IVb): or a pharmaceutically acceptable salt thereof, for use as pharmaceuticals, in particular for the treatment of a condition alleviated by antagonism of a 5-HT2B receptor.

  化合物的分子式：（I）、（II）、（IIIa）、（IIIb）、（IVa）和（IVb）：或其药用可接受的盐，用作药物，特别用于治疗通过拮抗5-HT2B受体缓解的病症。
• [EN] MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF<br/>[FR] MODULATEURS DU RECEPTEUR GLUCOCORTICOIDE AP-1, ET/OU DE L'ACTIVITE DE NF- DOLLAR G(K)B, ET LEUR UTILISATION
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005072732A1

  公开（公告）日：2005-08-11

  A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-ĸB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least one of X1 - X8 is N, and R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  提供了一类新型非类固醇化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-ĸB活性调节相关的疾病，包括肥胖、糖尿病、炎症和免疫性疾病，其结构如公式（I）所示，其立体异构体，或其溶剂化物，或其前药，或其药用可接受盐，其中Z为CONR1R2或CH2NR1R2，其中至少一个X1-X8为N，R、Ra、Rb、Rc和Rd在此处定义。还提供了包含所述化合物的药物组合物和治疗肥胖、糖尿病和炎症或免疫相关疾病的方法。
• Modulators of the glucocorticoid receptor, AP-1, and/or NF-kappaB activity and use thereof
  申请人：Duan Jingwu

  公开号：US20050176716A1

  公开（公告）日：2005-08-11

  A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR 1 R 2 or CH 2 NR 1 R 2 and where at least two of X 1 -X 4 and/or X 5 -X 8 is N or NR 18 , and R, R a , R b , R c , R d , R 1 , R 2 and R 18 are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  提供一类新型非甾体化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病，包括肥胖、糖尿病、炎症性和免疫性疾病，其结构如下所示：（I）及其立体异构体，或其溶剂化合物，或其前药，或其药理学上可接受的盐，其中Z是CONR1R2或CH2NR1R2，至少两个X1-X4和/或X5-X8是N或NR18，R、Ra、Rb、Rc、Rd、R1、R2和R18在此有所定义。还提供了包含这些化合物的药物组合物和治疗肥胖、糖尿病以及炎症性或免疫相关疾病的方法。
• [EN] MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF<br/>[FR] MODULATEURS DU RECEPTEUR DES GLUCOCORTICOIDES AP-1, ET/OU DE L'ACTIVITE DU NF-KB ET UTILISATION ASSOCIEE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005072729A1

  公开（公告）日：2005-08-11

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF­ KB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I), its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2 NR1R2 and where R, R', Ra, Rb, Rc, Rd, Z, A and B are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  提供了一种新型的非类固醇化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF­ KB活性调节相关的疾病，包括肥胖、糖尿病、炎症和免疫性疾病，其结构如下式（I），其立体异构体，或其溶剂化物，或其前药，或其药用可接受的盐，其中Z为CONR1R2或CH2 NR1R2，其中R、R'、Ra、Rb、Rc、Rd、Z、A和B在此处定义。还提供了含有该化合物的药物组合物和治疗肥胖、糖尿病以及炎症或免疫相关疾病的方法。
• Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof
  申请人：Yang Vera Bingwei

  公开号：US20050182110A1

  公开（公告）日：2005-08-18

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR 1 R 2 or CH 2 NR 1 R 2 and where R, R′, R a , R b , R c , R d , Z, A and B are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  提供了一些新型非甾体化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节有关的疾病，包括肥胖症、糖尿病、炎症性和免疫性疾病，其结构式为(I)及其立体异构体、溶剂化物、前药或药物可接受的盐，其中Z为CONR1R2或CH2NR1R2，R、R′、Ra、Rb、Rc、Rd、Z、A和B在此定义。还提供了含有该化合物的制药组合物和治疗肥胖症、糖尿病和炎症或免疫相关疾病的方法。